Dennis M J, French P C, Crome P, Babiker M, Shillingford J, Hopkins R
Br J Clin Pharmacol. 1985 Dec;20(6):567-73. doi: 10.1111/j.1365-2125.1985.tb05113.x.
The pharmacokinetics of ketoprofen following the administration of the first and final dose of a controlled release formulation (200 mg ketoprofen) once daily for 10 days to nine elderly patients have been studied. Plasma ketoprofen concentrations were measured by h.p.l.c. The data were compared to previously reported studies in young male volunteers. Mean +/- s.d. peak plasma concentrations (5.6 +/- 1.75 micrograms ml-1 and 6.3 +/- 2.7 micrograms ml-1 on day 1 and day 10, respectively) were higher than those reported in young volunteers given similar treatment, but similar to those reported in young volunteers following 50 mg four times daily of conventionally formulated ketoprofen, and markedly lower than reported following a single 100 mg dose of ketoprofen. The half-life for drug release (mean +/- s.d.) from the controlled release formulation (8.5 +/- 7.4 h) and accumulation upon repeated dosing (28%) were essentially the same as reported for young volunteers. The area under the plasma concentration-time curve was about 65% greater than reported in young volunteers following administration of controlled release ketoprofen. This increase in exposure to ketoprofen is probably partly due to the lower volume of distribution in the elderly and partly due to a reduced renal excretion of the glucuronide metabolite of ketoprofen. It was concluded that controlled release ketoprofen may be administered in standard doses (200 mg once daily) to elderly patients whose elimination processes are not severely impaired (i.e. severe renal failure or hepatic disease).(ABSTRACT TRUNCATED AT 250 WORDS)
研究了9名老年患者每日1次服用控释制剂(200毫克酮洛芬),连续10天,首剂和末剂给药后酮洛芬的药代动力学。采用高效液相色谱法测定血浆酮洛芬浓度。将数据与之前在年轻男性志愿者中进行的研究进行比较。平均±标准差的血浆峰浓度(第1天和第10天分别为5.6±1.75微克/毫升和6.3±2.7微克/毫升)高于接受类似治疗的年轻志愿者报告的浓度,但与年轻志愿者每日4次服用50毫克常规制剂酮洛芬后报告的浓度相似,且明显低于单次服用100毫克酮洛芬后报告的浓度。控释制剂的药物释放半衰期(平均±标准差)(8.5±7.4小时)和重复给药后的蓄积率(28%)与年轻志愿者报告的基本相同。血浆浓度-时间曲线下面积比服用控释酮洛芬后的年轻志愿者报告的约大65%。酮洛芬暴露量的增加可能部分归因于老年人分布容积较低,部分归因于酮洛芬葡萄糖醛酸代谢物肾排泄减少。得出结论,对于消除过程未严重受损(即严重肾衰竭或肝病)的老年患者,可按标准剂量(每日1次,200毫克)给予控释酮洛芬。(摘要截短于250字)